BACKGROUND: Accurate and economic detection of nerve damage in diabetes is key to more widespread diagnosis of patients with diabetic peripheral neuropathy (DPN) and painful diabetic neuropathy. This study examined the diagnostic performance of NerveCheck, an inexpensive ($500) quantitative sensory testing (QST) device. METHODS: One hundred forty-four subjects (74 with and 70 without diabetes) underwent assessment with NerveCheck, neuropathy disability score (NDS), nerve conduction studies (NCS), intraepidermal and corneal nerve fiber density (IENFD and CNFD), and McGill questionnaire for neuropathic pain. RESULTS: Of the 74 subjects with diabetes, 41 were diagnosed with DPN based on the NDS. The NerveCheck scores for vibration perception threshold (VPT), cold perception threshold (CPT), and warm perception threshold (WPT) were significantly lower (P ≤ 0.0001) in diabetic patients with DPN compared to patients without DPN. The diagnostic accuracy of VPT was high with reference to NCS (area under the curve [AUC]: 82%-84%) and moderate for IENFD, CNFD, and neuropathic pain (AUC: 60%-76%). The diagnostic accuracy of CPT and WPT was moderate with reference to NCS, IENFD, and CNFD (AUC: 69%-78%) and low for neuropathic pain (AUC: 63%-65%). CONCLUSIONS: NerveCheck is a low-cost QST device with good diagnostic utility for identifying sensory deficits, comparable to established tests of large and small fiber neuropathy and for the severity of neuropathic pain.
BACKGROUND: Accurate and economic detection of nerve damage in diabetes is key to more widespread diagnosis of patients with diabetic peripheral neuropathy (DPN) and painful diabetic neuropathy. This study examined the diagnostic performance of NerveCheck, an inexpensive ($500) quantitative sensory testing (QST) device. METHODS: One hundred forty-four subjects (74 with and 70 without diabetes) underwent assessment with NerveCheck, neuropathy disability score (NDS), nerve conduction studies (NCS), intraepidermal and corneal nerve fiber density (IENFD and CNFD), and McGill questionnaire for neuropathic pain. RESULTS: Of the 74 subjects with diabetes, 41 were diagnosed with DPN based on the NDS. The NerveCheck scores for vibration perception threshold (VPT), cold perception threshold (CPT), and warm perception threshold (WPT) were significantly lower (P ≤ 0.0001) in diabeticpatients with DPN compared to patients without DPN. The diagnostic accuracy of VPT was high with reference to NCS (area under the curve [AUC]: 82%-84%) and moderate for IENFD, CNFD, and neuropathic pain (AUC: 60%-76%). The diagnostic accuracy of CPT and WPT was moderate with reference to NCS, IENFD, and CNFD (AUC: 69%-78%) and low for neuropathic pain (AUC: 63%-65%). CONCLUSIONS: NerveCheck is a low-cost QST device with good diagnostic utility for identifying sensory deficits, comparable to established tests of large and small fiber neuropathy and for the severity of neuropathic pain.
Authors: Andrew J M Boulton; Arthur I Vinik; Joseph C Arezzo; Vera Bril; Eva L Feldman; Roy Freeman; Rayaz A Malik; Raelene E Maser; Jay M Sosenko; Dan Ziegler Journal: Diabetes Care Date: 2005-04 Impact factor: 19.112
Authors: Xin Chen; Jim Graham; Mohammad A Dabbah; Ioannis N Petropoulos; Georgios Ponirakis; Omar Asghar; Uazman Alam; Andrew Marshall; Hassan Fadavi; Maryam Ferdousi; Shazli Azmi; Mitra Tavakoli; Nathan Efron; Maria Jeziorska; Rayaz A Malik Journal: Diabetes Care Date: 2015-03-20 Impact factor: 19.112
Authors: Miroslav Misha Backonja; Nadine Attal; Ralf Baron; Didier Bouhassira; Mark Drangholt; Peter J Dyck; Robert R Edwards; Roy Freeman; Richard Gracely; Maija H Haanpaa; Per Hansson; Samar M Hatem; Elena K Krumova; Troels S Jensen; Christoph Maier; Gerard Mick; Andrew S Rice; Roman Rolke; Rolf-Detlef Treede; Jordi Serra; Thomas Toelle; Valeri Tugnoli; David Walk; Mark S Walalce; Mark Ware; David Yarnitsky; Dan Ziegler Journal: Pain Date: 2013-06-03 Impact factor: 6.961
Authors: Maija Haanpää; Nadine Attal; Miroslav Backonja; Ralf Baron; Michael Bennett; Didier Bouhassira; Giorgio Cruccu; Per Hansson; Jennifer A Haythornthwaite; Gian Domenico Iannetti; Troels S Jensen; Timo Kauppila; Turo J Nurmikko; Andew S C Rice; Michael Rowbotham; Jordi Serra; Claudia Sommer; Blair H Smith; Rolf-Detlef Treede Journal: Pain Date: 2010-09-19 Impact factor: 6.961
Authors: C A Abbott; A L Carrington; H Ashe; S Bath; L C Every; J Griffiths; A W Hann; A Hussein; N Jackson; K E Johnson; C H Ryder; R Torkington; E R E Van Ross; A M Whalley; P Widdows; S Williamson; A J M Boulton Journal: Diabet Med Date: 2002-05 Impact factor: 4.359
Authors: G Ponirakis; M N Odriozola; S Odriozola; I N Petropoulos; S Azmi; H Fadavi; U Alam; O Asghar; A Marshall; A Miro; A Kheyami; A Al-Ahmar; M B Odriozola; A Odriozola; R A Malik Journal: Diabetes Res Clin Pract Date: 2016-01-14 Impact factor: 5.602
Authors: Andreas C Themistocleous; Juan D Ramirez; Pallai R Shillo; Jonathan G Lees; Dinesh Selvarajah; Christine Orengo; Solomon Tesfaye; Andrew S C Rice; David L H Bennett Journal: Pain Date: 2016-05 Impact factor: 7.926